Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
argenx SE (ARGX): +24% Upside to the $1,150 Analyst Price Target?

argenx SE (ARGX): +24% Upside to the $1,150 Analyst Price Target?

Key Takeaways

  • The central $1,150 stock price target is the arithmetic mean of roughly 15 current, attributable analyst price targets, rounded to a clean level.
  • With ARGX trading near $925.70, reaching $1,150 requires an upside of about 24%, a substantial but not extreme move.
  • The analyst price target range is wide, from $861 (Baird) to $1,400 (UBS), reflecting genuine disagreement about how much Vyvgart growth is already priced in.
  • Strongest supports: rapid Vyvgart revenue growth, positive Phase 3 myositis data, and a mostly bullish analyst consensus.
  • Biggest risks: a late-2026 Sjögren's clinical setback, target trims at several firms, single-franchise concentration, and valuation sensitivity.
  • For more detail on Major News, Today's Price Move, the Forecast, and Earnings, explore Tickeron's dedicated ARGX pages.

Analyst Price Targets and Consensus View

argenx SE (ARGX) is a Netherlands-based, commercial-stage immunology company whose American Depositary Receipts trade on Nasdaq. It develops antibody-based therapies for severe autoimmune diseases, led by the Vyvgart (efgartigimod) franchise. Wall Street coverage is heavily bullish: most firms rate the stock Buy or Overweight, with a small neutral minority and no documented sell ratings in recent months.

Reviewing roughly 15 current, attributable 12-month price targets produces a range from $861 (Baird, Neutral) to $1,400 (UBS, Buy). The arithmetic mean of these targets is approximately $1,150, which I use as the central target. This is broadly consistent with aggregator figures, which place the average analyst price target between roughly $1,130 and $1,170. Recent action has moved both ways: Piper Sandler raised its target to $1,350 (November 2026) and UBS upgraded to Buy with a $1,400 target, while Morgan Stanley trimmed to $1,130 and several firms, including Citi, Guggenheim, RBC Capital, and Evercore ISI, cut targets after October's Sjögren's trial disappointment. The spread reflects different assumptions about how much of Vyvgart's multi-indication expansion is already reflected in the share price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

ARGX last closed near $925.70, giving it a market capitalization of roughly $58 billion and a 52-week range of about $661.85 to $1,072.75. Moving to $1,150 would require a gain of roughly 24% from current levels — a substantial move that would also take the stock above its 52-week high and into new all-time-high territory.

The path depends primarily on continued commercial execution and clinical catalysts. Vyvgart delivered about $4.15 billion in 2025 net revenue, and quarterly sales growth accelerated to roughly 60% year over year in Q2 2026, though a recent quarterly EPS figure of about $7.80 slightly missed consensus estimates. Analysts' reasoning centers on Vyvgart's expansion beyond generalized myasthenia gravis into CIDP and, potentially, myositis and other indications.

What Could Support a Move Toward the Target

  • Vyvgart momentum: Strong, accelerating revenue growth underpins most bullish price forecasts.
  • Clinical success: Positive Phase 3 Alkivia results (August 2026) showed Vyvgart Hytrulo helped autoimmune myositis patients, including immune-mediated necrotizing myopathy — a first for the field.
  • Label expansion potential: Upcoming readouts in multifocal motor neuropathy, CIDP, and immune thrombocytopenia could widen the addressable market.
  • Favorable analyst revisions: Upgrades and target raises at UBS and Piper Sandler signal continued conviction despite some trims.

What Could Prevent the Target From Being Reached

  • Clinical setbacks: The October 2026 Sjögren's trial miss triggered a wave of target reductions and highlights pipeline risk.
  • Single-franchise concentration: Revenue depends almost entirely on Vyvgart, so any competitive or safety surprise would weigh heavily.
  • Valuation sensitivity: With a P/E ratio around 30, growth must continue to justify the multiple.
  • Broad market risk: High-growth biotech tends to be vulnerable to risk-off rotations and rising-rate pressure.

Technical Levels and Market Structure

ARGX trades near $925.70, below its 52-week high of $1,072.75 and well above its 52-week low of $661.85. The prior high near $1,073 is a meaningful resistance level, and the psychologically important $1,000 mark sits just above the current price. A durable support level is harder to define on the upside journey, but the stock has repeatedly found buying interest in the mid-$800s during recent pullbacks. Reaching $1,150 would require clearing $1,000 and then the $1,073 record high — both technically significant hurdles.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors watching this target should monitor quarterly Vyvgart sales and EPS, upcoming late-stage readouts (including empraisprubart data expected in the fourth quarter of 2026 and later CIDP results), further analyst target revisions, and any regulatory or reimbursement developments. Broader biotech sentiment and interest-rate expectations also matter for a high-multiple growth name. From what I see, monitoring these catalysts remains essential.

AI Daily Buy/Sell Signals

When reviewing a stock like ARGX, where price moves often hinge on clinical data and analyst updates, I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking automated signals based on technical behavior and market conditions. In my view, this kind of AI-driven monitoring adds efficiency when following names with event-driven volatility, allowing a clearer view of shifting trends alongside manual analysis.

Final Assessment

The central $1,150 target is an analyst-derived average, not a guarantee. It requires a roughly 24% advance from $925.70 — a substantial move that would push ARGX to new highs. The case rests on Vyvgart's commercial momentum and a broad late-stage pipeline, while the principal obstacles are a recent clinical miss, single-product concentration, and a rich valuation. With targets spanning $861 to $1,400, analysts themselves disagree sharply on how far the stock can go, so the key question is whether continued revenue growth and positive readouts can overcome the market's valuation caution. I'm watching this closely as new data emerges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARGX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARGX in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 09, 2026

ARGX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 26 of the 39 cases the stock fell afterwards. This puts the odds of success at 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where ARGX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARGX as a result. In 50 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARGX's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.

ARGX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARGX crossed bullishly above the 50-day moving average on November 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +1.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 215 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

The Aroon Indicator entered an Uptrend today. In 180 of 256 cases where ARGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.892) is normal, around the industry mean (3.596). P/E Ratio (33.413) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (443.347).

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of antibody-based medicines

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
Laarderhoogtweg 25
Phone
+31 107038441
Employees
3522
Web
https://www.argenx.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.
argenx SE (ARGX): +24% Upside to the $1,150 Analyst Price Target?